Expert-recommended "once‑in‑a‑lifetime" testing for Lp(a) introduces new clinical supply risks as screening drives volatility, longer treatment, and inventory strain.
- What CAPAs Don't Catch: 3 Hidden ATMP Cold Chain Vulnerabilities By Design
- AI And Digital Tools Advance Clinical Trial Supply Chains
- Solving Pharmacy And Clinical Supply Challenges In Decentralized Trials
- How The Strait Of Hormuz Crisis Is Stalling U.S. Medical Breakthroughs
- The Hidden Bottleneck: Clinical Supply Strategy In Study Start-Up
- Why More Tools Won't Fix Clinical Supply
- The Hidden Supply Chain Risks That Can Derail Small Biotech Trials
- What's Breaking In Clinical Trial Supply — And How To Fix It
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Unblinding Risks In RTSM: What's Still Going Wrong, And How Korio Fixes It
Protecting study integrity requires more than just luck. Learn how systemic gaps lead to unintentional unblinding and how a proactive, engine-based approach can safeguard your clinical data.
-
Building Clinical Supply Agility In A Changing Trial Landscape
Rising trial complexity demands agile supply built on integrated operations, solid planning, and fast issue resolution. Lean teams gain from partners providing flexibility, control, and global reach.
-
Sponsor Overcomes Hold And Steers Products Through Development
Uncover how a small-sized biotech company was able to resolve critical regulatory CMC deficiencies to meet FDA requirements.
-
Advantages Of Sourcing Biosimilars Vs. Branded Biologics In Clinical Trials
Evaluate biosimilar alternatives during clinical trial planning to reduce comparator drug costs and improve overall study efficiency without compromising trial integrity.
-
Compressing Analytical Timelines Without Cutting Corners
Efficient analytical development speeds decisions and improves risk visibility. Using QbD, digital tools, and strong communication helps teams accelerate timelines while maintaining rigor.
-
Is Your Clinical Supply Strategy Ready For EU CTR?
One of the most significant changes in the new EU regulation is Annex VI, which covers changes in the labelling requirements for investigational medical products (IMPs). So, what are the implications of these changes and how will they affect outer immediate packaging?
-
RTSM Manages Clinical IP Dispensation In Schizophrenia Study
Challenged by the dispensation of an investigational product (IP) across diverse patient subgroups, see what solution this pharma was able to utilize to ensure optimal distribution and minimize wastage.
-
3 Study Areas Where Your IRT Vendor Should Do More
Find out how advanced IRT systems now support diverse trial designs and how the expertise of RTSM vendors is crucial for tailoring solutions to trial needs and providing ongoing support.
-
Building Robust Clinical Supply Chains To Support Global Trials
Ensuring drugs reach patients at the right time and place is crucial. Review key areas to consider as you build a robust clinical supply chain that supports global trials effectively and efficiently.
-
Quality Assured: Bringing Life-Changing Therapies To Patients
Biopharmaceutical drug development remains a key trend, demanding specific expertise and capabilities when it comes to quality assurance. Explore four trends that matter in biologics for clinical trial supply.
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.